Evidence and limits
How strong the evidence is for each component
Evidence is graded on this page in four words: strong, moderate, emerging and limited. A component graded limited or emerging is an individual treatment attempt decided with the patient after medical consultation, and the physician says so before you consent.
Local-regional hyperthermia with chemotherapy or radiotherapy: strong for defined indications. A randomized phase 3 trial in 341 patients with high-risk soft-tissue sarcoma found better local progression-free survival when regional hyperthermia was added to chemotherapy (Issels et al., Lancet Oncol, 2010), and the long-term analysis found longer survival as well (Issels et al., JAMA Oncol, 2018). In recurrent breast cancer, a meta-analysis of 34 studies found complete responses more often with hyperthermia added to radiotherapy than with radiotherapy alone (Datta et al., Int J Radiat Oncol Biol Phys, 2016).
Mistletoe therapy: moderate for quality of life. A meta-analysis of nine randomized trials in breast cancer found a medium-sized improvement in quality of life (Loef et al., Integr Cancer Ther, 2023), and one randomized trial in pancreatic cancer no longer treatable by surgery, without further tumor treatment, found longer survival with mistletoe than with supportive care alone (Tröger et al., Eur J Cancer, 2013).
Supportive and mind-body measures: the Society for Integrative Oncology guideline recommends meditation, yoga, relaxation and music therapy for anxiety and mood during breast cancer treatment and acupressure or acupuncture for chemotherapy-induced nausea, and finds no strong evidence that ingested supplements manage treatment side effects (Greenlee et al., CA Cancer J Clin, 2017). High-dose vitamin C: limited for an anti-tumor effect; a randomized phase 3 trial in 442 patients with metastatic colorectal cancer found no longer progression-free survival when it was added to chemotherapy (Wang et al., Clin Cancer Res, 2022). Whole-body hyperthermia in oncology, IPT and dendritic cell therapy: emerging to limited, from cohort and early-phase data.
What the evidence does not show is a survival benefit for the integrative program as a whole in a controlled trial, and the hospital does not claim one. What we can show is the measurement: tumor markers, immune status and organ function before the first session and again in week two, documented in the report your oncologist receives.